Publications by authors named "Parmana I"

Article Synopsis
  • On-pump coronary artery bypass grafting (CABG) is a common surgery for coronary artery disease but can trigger systemic inflammatory responses that increase patient risks.
  • This study analyzed data from 1,056 patients who underwent on-pump CABG from 2019 to 2022, identifying the systemic immune-inflammation index (SII) as a key predictor of surgical outcomes.
  • Higher preoperative SII values were linked to longer surgeries, increased need for mechanical ventilation, extended ICU and hospital stays, as well as greater risks of complications like atrial fibrillation and mortality.
View Article and Find Full Text PDF

Purpose: Coronary artery disease (CAD) is the primary cause of mortality in developing countries. Off-pump coronary artery bypass grafting (OPCAB) offers more upside in revascularization by preventing cardiopulmonary bypass trauma and minimizing aortic manipulation. Even though cardiopulmonary bypass is not involved, OPCAB still causes a significant systemic inflammatory response.

View Article and Find Full Text PDF

Purpose: On-pump coronary artery bypass graft (CABG) causes myocardial ischemia, through the cardiopulmonary bypass (CPB) and aortic cross-clamping (AoX). Glutamine supplementation protects cardiac cells during cardiac ischemia. This study analysed the correlation between cardiac index (CI), plasma troponin I, myocardial histopathology, CPB and AoX duration in low ejection fraction patients receiving glutamine and no glutamine undergoing elective on-pump CABG.

View Article and Find Full Text PDF

Purpose: Myocardial injury due to on-pump coronary artery bypass grafting (CABG) in patients with low ejection fraction (EF) is associated with poor outcomes. This study determines whether intravenous glutamine could protect the myocardium during on-pump CABG in patients with low EF.

Materials And Methods: This was a double-blind, randomized controlled trial to assess glutamine as a myocardial protector during on-pump CABG in patients with left ventricle EF of 31-50%, conducted from January to October 2021.

View Article and Find Full Text PDF